For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Ghrelin vs GHRP-2

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GhrelinGHRP-2
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asGHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelinGrowth Hormone Releasing Peptide-2, Pralmorelin, KP 102
EvidenceInvestigational (in trials)Preclinical only
Dosing range0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal100mcg–300mcg mcg, 1–3 times daily, on an empty stomach
AdministrationIntravenous (research), Subcutaneous injectionSubcutaneous injection, Intramuscular injection
Key side effectsAppetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulationIncreased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritation
Cited sources2 references3 references

Key differences

  • Evidence level differs: Ghrelin is investigational (in trials), while GHRP-2 is preclinical only.
  • Administration: Ghrelin — Intravenous (research), Subcutaneous injection; GHRP-2 — Subcutaneous injection, Intramuscular injection.
  • Dosing units differ: Ghrelin is dosed in mcg/kg, GHRP-2 in mcg — they operate at different scales.
  • Frequency: Ghrelin is typically IV or SC bolus; endogenous levels peak pre-meal; GHRP-2 is 1–3 times daily, on an empty stomach.
  • Research depth: this profile cites 2 sources for Ghrelin vs 3 for GHRP-2.

How each works

Ghrelin

Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.

GHRP-2

GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.

Read the full Ghrelin profileRead the full GHRP-2 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.